Immunotherapy, which harnesses the power of the body's immune system to fight disease, is gaining huge traction in treating cancer.
Scooped by BigField GEG Tech |
woodfieldplumbingandheating's comment,
October 18, 2021 2:16 AM
good
sofia carlos's curator insight,
April 10, 2022 8:43 PM
https://www.bostonterrierpetshome.com https://www.bostonterrierpetshome.com https://www.bostonterrierpetshome.com https://www.bostonterrierpetshome.com https://www.bostonterrierpetshome.com
Pierre-Luc Jellimann 's curator insight,
October 23, 2022 10:52 AM
Etude intéressante sur l'efficacité des CAR-T cells et surtout des TCR-T cells dans le traitement des tumeurs solides (mélanomes++)
Sign up to comment
In the new study, Dr. Sykulev and colleagues in Takami Sato's lab engineered CAR-T cells to recognize an antigen on melanoma cells called high molecular weight melanoma-associated antigen (HMW-MAA). Melanoma cells express varying amounts of HMW-MAA on their cell surfaces. In their research, the researchers evaluated the extent to which CAR-T cells killed melanoma cells. They found that CAR-T cells effectively killed melanoma cells expressing high levels of HMW-MAA, but not those with lower levels of the antigen. The researchers then tested how well another type of immunotherapy, known as TCR-T cells that uses T cells engineered to express a specific T-cell receptor, killed the target cells. When the researchers treated melanoma cells with TCR-T cells, they found that the treatment readily killed tumor cells, even in melanoma cell lines that expressed far less HMW-MAA antigens than needed for CAR-T. The comparison thus revealed that TCR-T is superior to CAR-T therapy for melanoma.